VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial
Biopharma & Life Sciences

Bausch Health Companies Executive Compensation (FY25)

BHC · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Thomas Appio
Latest say-on-pay support
=
May 19, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
See every company’s exec pay — free for 3 days, no cardSee the plan and pricing
Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.

The paid brief on Bausch Health Companies

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Get the executive briefGet the board briefNo account needed.
Data as of November 5, 2026Latest filing (8-K): May 19, 2026
14 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Bausch Health Companies brief$500Get the executive brief
Velarion Intel, one year, every company
318 figures on this page: 308 cited to the filing that reported them, 10 calculated from figures it prints. See the citations

More on Bausch Health Companies

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Thomas Appio: $16,239,133 → $16,877,326 (3.9% higher)
CEO pay ratio: 370:1 → 401:1 (8.4% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Bausch Health Companies' chief executive and what were they paid?
Thomas Appio, Chief Executive Officer, received $16,877,326 in total compensation for fiscal 2025. Compared with the $16,239,133 reported for fiscal 2024, Appio's total was 3.9% higher.
What was Bausch Health Companies' say-on-pay result?
Shareholders supported the say-on-pay proposal with 95.2% of votes cast for or against in favor at the meeting held May 19, 2026 for fiscal 2025.
Which companies are in Bausch Health Companies' peer group?
The disclosed peer group includes Biogen Inc., BioMarin Pharmaceutical Inc., Elanco Animal Health Incorporated, Hologic, Inc. and Incyte Corporation, among others.
What is Bausch Health Companies' chief executive pay ratio?
The company reported a chief executive pay ratio of 401:1 for fiscal 2025, against median employee compensation of $42,062.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Joseph Papa
Former Chief Executive Officer
Departed during or after this year
◇—◇◇◇—◇◇
Thomas Appio
Chief Executive Officer
◇—◇◇◇—◇◇
Tom Vadaketh
Executive Vice President and Chief Financial Officer
◇◇◇◇◇—◇◇
Sam Eldessouky
Former Executive Vice President and Chief Financial Officer
Departed during or after this year
◇—◇◇◇—◇◇
Christina Ackermann
Former Executive Vice President and General Counsel and Head of Commercial Operations
Departed during or after this year
◇—◇◇◇—◇◇
Robert Spurr
Former President US Pharmaceutical Business
Departed during or after this year
◇—◇◇——◇◇
Seana Carson
Executive Vice President and General Counsel
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Thomas Appio
Chief Executive Officer
◇—◇—◇—◇◇
Tom Vadaketh
Former Executive Vice President and Chief Financial Officer
Departed during or after this year
◇—◇◇——◇◇
Seana Carson
Executive Vice President, General Counsel
◇—◇◇◇—◇◇
John Barresi
Senior Vice President, Controller, Chief Accounting Officer and Interim Chief Financial Officer
◇◇◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Thomas Appio
Chief Executive Officer
◇—◇—◇—◇◇
Jean-Jacques Charhon
Executive Vice President, Chief Financial Officer
◇◇◇—◇——◇
Seana Carson
Executive Vice President, General Counsel
◇—◇—◇—◇◇
Aimee Lenar
Executive Vice President, US Pharma
◇◇◇—◇—◇◇
John Barresi
Senior Vice President, Controller and Chief Accounting Officer
◇◇◇—◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Thomas Appio
Chief Executive Officer
◇◇◇—◇—◇◇
Jean-Jacques Charhon
Executive Vice President, Chief Financial Officer
◇—◇—◇—◇◇
Seana Carson
Executive Vice President, General Counsel
◇◇◇—◇—◇◇
Aimee Lenar
Executive Vice President, US Pharma
◇—◇—◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Aimee J. LenarPSU◇◇◇—◇—◇
Aimee J. LenarRSU◇——◇——◇
Aimee J. LenarRSU◇——◇——◇
Jean-Jacques CharhonRSU◇——◇——◇
Jean-Jacques CharhonPSU◇◇◇—◇—◇
Seana CarsonPSU◇◇◇—◇—◇
Seana CarsonRSU◇——◇——◇
Thomas J. AppioPSU◇◇◇—◇—◇
Thomas J. AppioRSU◇——◇——◇
Fiscal 2022 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Seana CarsonOption◇—◇3/2/2032
Option◇—◇6/9/2026
Option◇—◇2/27/2029
Option◇—◇2/26/2030
RSU◇◇——
Option◇—◇3/3/2031
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇3/2/2033
RSU◇◇——
Thomas AppioOption◇—◇3/2/2032
Option◇—◇2/26/2030
Option◇—◇2/27/2029
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇3/7/2028
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇3/1/2027
Option◇—◇3/3/2031
Jean-Jacques CharhonRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Aimee LenarRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Aimee Lenar
Executive Vice President, US Pharma · Employment agreement
Severance multiple◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Jean-Jacques Charhon
Executive Vice President, Chief Financial Officer · Severance agreement
Severance multiple◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Seana Carson
Executive Vice President, General Counsel · Severance agreement
Severance multiple◇
Severance cash amount◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Thomas Appio
Chief Executive Officer · Employment agreement
Severance multiple◇
Severance cash amount◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
John A. Paulson
Board chair
◇◇————◇
Sarah B. Kavanagh
◇◇————◇
Brett M. Icahn
◇◇————◇
Robert N. Power
◇◇————◇
Frank D. Lee
◇◇————◇
Amy B. Wechsler
◇◇————◇
Christian A. Garcia
◇◇————◇
Richard C. Mulligan
◇◇————◇
Steven D. Miller
◇◇————◇
Michael Goettler
◇◇————◇
Sandra Leung
—◇————◇
Thomas J. Appio and Eiry W. Roberts served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Biogen Inc. BIIB
  • BioMarin Pharmaceutical Inc. BMRN
  • Elanco Animal Health Incorporated ELAN
  • Hologic, Inc. HOLX
  • Incyte Corporation INCY
  • Jazz Pharmaceuticals plc JAZZ
  • Organon & Co. OGN
  • Perrigo Company plc PRGO
  • Steris plc STE
  • Teva Pharmaceutical Industries Limited TEVA
  • United Therapeutics Corporation UTHR
  • Viatris Inc. VTRS
  • Zimmer Biomet Holdings Inc. ZBH

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025May 19, 2026=◇◇◇
2023May 14, 2024=◇◇◇
2022May 16, 2023=◇◇◇
2021May 2, 2022=◇◇◇
2020April 27, 2021=◇◇◇
2019April 28, 2020=◇◇◇
2018April 30, 2019=◇◇◇
2017April 30, 2018=◇◇◇
2016May 2, 2017=◇◇◇
2015June 14, 2016=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Thomas Appio (Chief Executive Officer), FY2025 total compensation $16,877,326 (base salary $1,236,000) [exec_comp, SEC accession 0001140361-26-013816, filed 2026-04-08]

See a complete sample report

Answered within 24 hours, every figure cited to its SEC filing. This is a one-off report: no refunds.

Tell me when Bausch Health Companies files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Bausch Health Companies disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Bausch Health Companies sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Bausch Health Companies' disclosed peer group is defensible, who names Bausch Health Companies back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
318 figures on this page: 308 cited to the filing that reported them, 10 calculated from figures it prints.
308 cited to the filing
10 calculated from the filing

Documents cited

  1. 0000885590-26-000057
    Item 5.07. Submission of Matters to a Vote of Security Holders.
  2. 0001140361-26-013816
    2025 SUMMARY COMPENSATION TABLE · Compensation Discussion and Analysis · DIRECTOR COMPENSATION TABLE · Grants of Plan-Based Awards · and 2 more sections
  3. 0001140361-25-011851
    SUMMARY COMPENSATION TABLE
  4. 0000885590-24-000021
    Item 5.07. Submission of Matters to a Vote of Security Holders.
  5. 0001140361-24-017937
    2023 SUMMARY COMPENSATION TABLE · SUMMARY COMPENSATION TABLE
  6. 0000885590-23-000021
    Item 5.07. Submission of Matters to a Vote of Security Holders.
  7. 0001140361-23-017057
    SUMMARY COMPENSATION TABLE
  8. 0001193125-22-180408
    Item 5.07. Submission of Matters to a Vote of Security Holders.
  9. 0000885590-21-000022
    Item 5.07. Submission of Matters to a Vote of Security Holders.
  10. 0000885590-20-000023
    Item 5.07 Submission of Matters to a Vote of Security Holders.
  11. 0000885590-19-000011
    Item 5.07. Submission of Matters to a Vote of Security Holders.
  12. 0000885590-18-000023
    Item 5.07. Submission of Matters to a Vote of Security Holders.
  13. 0000950103-17-004319
    Item 5.07. Submission of Matters to a Vote of Security Holders.
  14. 0001193125-16-622397
    Item 5.07. Submission of Matters to a Vote of Security Holders.
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Bausch Health Companies executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/BHC (accessed 2026).
Short form: data: Velarion

The paid brief for Bausch Health Companies

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Get the executive briefGet the board briefNo account needed.
14 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Bausch Health Companies and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Bausch Health Companies discloses

The companies named in BHC's own disclosed peer group.

Biogen Inc.BioMarin Pharmaceutical Inc.Elanco Animal Health IncorporatedHologic, Inc.Incyte CorporationJazz Pharmaceuticals plcOrganon & Co.Perrigo Company plcSteris plcTeva Pharmaceutical Industries LimitedUnited Therapeutics CorporationViatris Inc.Zimmer Biomet Holdings Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy